You have matched to 5 trials

Guest Profile:  Lobular

Sort by zip code: 94107 Hide Map Icon
mail-icon

Register to sign up for Trial Alerts

Receive emails about new trials that match your profile.
1

PLUMB Registry for Metastatic <span class="highlight">Lobular</span> Breast Cancer

Improving Survival for Those With Metastatic <span class="highlight">Lobular</span> Breast Cancer Through Development of the Multi-center PLUMB Registry-a Prospective Study of <span class="highlight">LobUlar</span> Metastatic Breast Cancer

Purpose: To create a registry to study metastatic <span class="highlight">lobular</span> breast cancer, treatment patterns, and overall survival.

Who is this for?: People with stage IV (metastatic) <span class="highlight">lobular</span> breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood samples</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood samples will be used to study the relationship between ctDNA and disease progression.</li> <li class="seamTextUnorderedListItem">Circulating tumor DNA (ctDNA) are small pieces of cancer cell DNA in the bloodstream.</li> <li class="seamTextUnorderedListItem">This trial will also develop an ongoing platform for evaluating new imaging tools, tumor markers, and participant recruitment for clinical trials.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05964504' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://clinicaltrials.ucsf.edu/trial/NCT05964504' target='_blank'>University of California, San Francisco: Trial Information Page</a> </li></ul>
1

PLUMB Registry for Metastatic <span class="highlight">Lobular</span> Breast Cancer

Improving Survival for Those With Metastatic <span class="highlight">Lobular</span> Breast Cancer Through Development of the Multi-center PLUMB Registry-a Prospective Study of <span class="highlight">LobUlar</span> Metastatic Breast Cancer
Icon

Nearest Location:
5 miles
University of California, San Francisco
San Francisco, CA

Icon

Visits:
Coincides with routine care

Icon

ClinicalTrials.gov: NCT05964504

Icon

Phase NA

2

Using a PET/CT Scan to Find <span class="highlight">Lobular</span> Breast Cancer Cells Before Surgery for Stage I-IV <span class="highlight">Lobular</span> Breast Cancer

[18F]Fluoroestradiol-PET/CT Imaging of Invasive <span class="highlight">Lobular</span> Carcinoma

Purpose: To study whether a PET/CT scan using a (18F) FES tracer is more effective at finding <span class="highlight">lobular</span> breast cancer cells than the standard of care.

Who is this for?: People diagnosed with stage I, stage II or stage III <span class="highlight">lobular</span> breast cancer within the last 3 months and who have not yet had surgery and people with stage IV (metastatic) <span class="highlight">lobular</span> breast cancer diagnosed within the last 3 months View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/CT scan using (18F) FES tracer, 1 time</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer. A tracer looks for and attaches to cancer cells.</li> <li class="seamTextUnorderedListItem">Lobular breast cancer is a subtype of breast cancer. It is estimated that 10 to 15 percent of all breast cancers are <span class="highlight">lobular.</span> </li> <li class="seamTextUnorderedListItem">Standard of care PET/CT scans that use a FDG tracer generally do not find <span class="highlight">lobular</span> breast cancer tumors as well as they find ductal breast cancer tumors and PET/CT scans are not usually given to people with stage I-II <span class="highlight">lobular</span> breast cancer. </li> <li class="seamTextUnorderedListItem">This imaging trial will use a tracer called (18F)Fluoroestradiol (FES). Researchers believe this tracer is better at locating and attaching to <span class="highlight">lobular</span> cancer cells than the standard of care tracer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04252859' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://lobularbreastcancer.org/imagingilc/' target='_blank'>Lobular Breast Cancer Alliance: Imaging and Lobular Breast Cancer</a> </li></ul>
2

Using a PET/CT Scan to Find <span class="highlight">Lobular</span> Breast Cancer Cells Before Surgery for Stage I-IV <span class="highlight">Lobular</span> Breast Cancer

[18F]Fluoroestradiol-PET/CT Imaging of Invasive <span class="highlight">Lobular</span> Carcinoma
Icon

Nearest Location:
602 miles
Huntsman Cancer Institute
Salt Lake City, UT

Icon

Visits:
1 visit

Icon

ClinicalTrials.gov: NCT04252859

Icon

Phase II

3

PET/CT Scan for Detecting Metastasis in <span class="highlight">Lobular</span> Breast Cancer

A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer

Purpose: To determine whether PET/CT scans with piflufolastat F18 (PYLARIFY®) can be used to detect metastasis of breast cancer.

Who is this for?: People with metastatic (stage IV) <span class="highlight">lobular</span> breast cancer or stage I, stage II, or stage III <span class="highlight">lobular</span> breast cancer that is suspected to have spread. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Piflufolastat F18 (PYLARIFY®), by IV, 1 time</li> <li class="seamTextUnorderedListItem">PET/CT scan, 1 time</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Piflufolastat F18 (PYLARIFY®) is a tracer that is used to detect metastasis in people with prostate cancer. This trial will determine if it can also be used for breast cancer.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05394259' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/drugs-supplements/piflufolastat-f-18-intravenous-route/description/drg-20516701' target='_blank'>Mayo Clinic: Piflufolastat F18 (PYLARIFY®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/cancer-in-general/tests/pet-ct-scan' target='_blank'>Cancer Research UK: PET/CT Scan</a> </li></ul>
3

PET/CT Scan for Detecting Metastasis in <span class="highlight">Lobular</span> Breast Cancer

A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer
Icon

Nearest Location:
1643 miles
MD Anderson Cancer Center
Houston, TX

Icon

Visits:
1 visit

Icon

ClinicalTrials.gov: NCT05394259

Icon

Phase I

4

Biomarkers to Detect Resistance to Hormone Therapy for Advanced HR+, HER2- <span class="highlight">Lobular</span> Breast Cancer

Integrating Minimally Invasive Biomarkers of Estrogen Signaling to Detect Endocrine Therapy Resistance in Metastatic Invasive <span class="highlight">Lobular</span> Breast Cancer

Purpose: To identify possible biomarkers of response to hormone therapy for advanced <span class="highlight">lobular</span> breast cancer.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ or ER low and/or PR+ or PR low), HER2 negative (HER2-) <span class="highlight">lobular</span> breast cancer (LBC) who are planning to receive hormone therapy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/CT scans with 18F-FFNP, by IV, 2 times within 1 month</li> <li class="seamTextUnorderedListItem">Blood tests, 2 times within 1 month</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biomarkers are genes, molecules, or other features present in a person, including in a person’s tumor, that tell doctors something about a person’s health condition.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">The tracer used in this study is 18F-FFNP.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy. MRI scans study the blood vessels in the tumor. PET/CT scans study if the tumor cells are growing.</li> <li class="seamTextUnorderedListItem">The blood samples will be used to conduct DNA and circulating tumor cell (CTC) testing.</li> <li class="seamTextUnorderedListItem">Circulating tumor cells (CTCs) are cancer cells from a tumor that circulate in the bloodstream.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06067503' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/treatment/types/biomarker-testing-cancer-treatment' target='_blank'>National Cancer Institute: Biomarker Testing</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/pet-scans' target='_blank'>Breastcancer.org: PET Scans</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/ct-scan' target='_blank'>Breastcancer.org: CT Scans</a> </li></ul>
4

Biomarkers to Detect Resistance to Hormone Therapy for Advanced HR+, HER2- <span class="highlight">Lobular</span> Breast Cancer

Integrating Minimally Invasive Biomarkers of Estrogen Signaling to Detect Endocrine Therapy Resistance in Metastatic Invasive <span class="highlight">Lobular</span> Breast Cancer
Icon

Nearest Location:
1678 miles
UW Carbone Cancer Center
Madison, WI

Icon

Visits:
2 visits within 1 month

Icon

ClinicalTrials.gov: NCT06067503

Icon

Phase II

5

Epidiferphane Nutritional Supplement with Chemotherapy for Stage I-IV Breast Cancer

Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of epidiferphane, an experimental nutritional supplement, with chemotherapy.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning on receiving treatment with chemotherapy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Epidiferphane, by mouth, daily for 3 months</li> <li class="seamTextUnorderedListItem">Physician's choice of chemotherapy: Docetaxel (Taxotere®), every 3 weeks; paclitaxel (Taxol®), weekly; or nab-paclitaxel (Abraxane®), weekly; 3 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Epidiferphane is an experimental nutritional supplement that may reduce chemotherapy symptoms.</li> <li class="seamTextUnorderedListItem">Docetaxel (Taxotere®), paclitaxel (Taxol®), and nab-paclitaxel (Abraxane®) are chemotherapy drugs.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with <span class="highlight">lobular</span> breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05074290' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/epidiferphane' target='_blank'>National Cancer Institute: Epidiferphane</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/chemotherapy' target='_blank'>Breastcancer.org: Chemotherapy</a> </li></ul>
5

Epidiferphane Nutritional Supplement with Chemotherapy for Stage I-IV Breast Cancer

Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients
Icon

Nearest Location:
2351 miles
University of Florida
Gainesville, FL

Icon

Visits:
1 visit every 1-3 weeks for 3 months

Icon

ClinicalTrials.gov: NCT05074290

Icon

Phase I-II

HELP GUIDE
HELP GUIDE